We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
We are committed to bringing more of our medicines to more people, no matter where they are.
People and Culture
Novartis is building an Inspired, Curious and Unbossed culture.
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Novartis completes divestment of ‘front of eye’ ophthalmology assets
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way
Novartis has been at the forefront of advances in how blood cancers and serious blood disorders are treated, helping patients live their best lives.
Environmental, Social and Governance
We have a responsibility and opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.
The Novartis Commitment to Patients and Caregivers
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives.